rs760123202
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_012472.6(DNAAF11):βc.630delβ(p.Trp210CysfsTer12) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000987 in 1,611,532 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.0000066 ( 0 hom., cov: 32)
Exomes π: 0.00011 ( 0 hom. )
Consequence
DNAAF11
NM_012472.6 frameshift
NM_012472.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.74
Genes affected
DNAAF11 (HGNC:16725): (dynein axonemal assembly factor 11) The protein encoded by this gene contains several leucine-rich repeat domains and appears to be involved in the motility of cilia. Defects in this gene are a cause of primary ciliary dyskinesia-19 (CILD19). Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 4, 11 and 22. [provided by RefSeq, Apr 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 8-132632762-AC-A is Pathogenic according to our data. Variant chr8-132632762-AC-A is described in ClinVar as [Pathogenic]. Clinvar id is 208996.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-132632762-AC-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAAF11 | NM_012472.6 | c.630del | p.Trp210CysfsTer12 | frameshift_variant | 5/12 | ENST00000620350.5 | NP_036604.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAAF11 | ENST00000620350.5 | c.630del | p.Trp210CysfsTer12 | frameshift_variant | 5/12 | 1 | NM_012472.6 | ENSP00000484634 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152208Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152208
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000175 AC: 44AN: 251336Hom.: 0 AF XY: 0.000250 AC XY: 34AN XY: 135842
GnomAD3 exomes
AF:
AC:
44
AN:
251336
Hom.:
AF XY:
AC XY:
34
AN XY:
135842
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000108 AC: 158AN: 1459324Hom.: 0 Cov.: 30 AF XY: 0.000165 AC XY: 120AN XY: 726184
GnomAD4 exome
AF:
AC:
158
AN:
1459324
Hom.:
Cov.:
30
AF XY:
AC XY:
120
AN XY:
726184
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152208Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74362
GnomAD4 genome
AF:
AC:
1
AN:
152208
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74362
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Primary ciliary dyskinesia 19 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 08, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 28, 2023 | This sequence change creates a premature translational stop signal (p.Trp210Cysfs*12) in the LRRC6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LRRC6 are known to be pathogenic (PMID: 23122589). This variant is present in population databases (rs760123202, gnomAD 0.1%). This premature translational stop signal has been observed in individuals with primary ciliary dyskinesia (PMID: 23891469, 24307375). ClinVar contains an entry for this variant (Variation ID: 208996). For these reasons, this variant has been classified as Pathogenic. - |
DNAAF11-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 23, 2024 | The DNAAF11 c.630delG variant is predicted to result in a frameshift and premature protein termination (p.Trp210Cysfs*12). This particular variant has been reported in the homozygous state in multiple unrelated individuals with primary ciliary dyskinesia with or without situs inversus (Zariwala et al. 2013. PubMed ID: 23891469; Watson et al. 2014. PubMed ID: 24307375, Table S8; Marshall et al. 2015. PubMed ID: 26139845). This variant is reported in 0.13% of alleles in individuals of South Asian descent in gnomAD and has been classified as pathogenic in ClinVar. Frameshift variants in DNAAF11 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Primary ciliary dyskinesia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 19, 2017 | The c.630delG pathogenic mutation, located in coding exon 5 of the LRRC6 gene, results from a deletion of one nucleotide at nucleotide position 630, causing a translational frameshift with a predicted alternate stop codon (p.W210Cfs*12). This mutation was identified in the homozygous state in affected individuals from 7 primary ciliary dyskinesia families (Zariwala MA et al. Am. J. Hum. Genet., 2013 Aug;93:336-45; Marshall CR et al. G3 (Bethesda), 2015 Jul;5:1775-81). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Kartagener syndrome Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at